NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis $1.58 +0.04 (+2.60%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.32%) As of 08/22/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Humacyte Stock (NASDAQ:HUMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Humacyte alerts:Sign Up Key Stats Today's Range$1.50▼$1.6150-Day Range$1.54▼$2.7352-Week Range$1.15▼$7.48Volume3.56 million shsAverage Volume6.29 million shsMarket Capitalization$245.09 millionP/E RatioN/ADividend YieldN/APrice Target$10.64Consensus RatingBuy Company Overview Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Read More Humacyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreHUMA MarketRank™: Humacyte scored higher than 47% of companies evaluated by MarketBeat, and ranked 595th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHumacyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHumacyte has only been the subject of 3 research reports in the past 90 days.Read more about Humacyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($1.27) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 52.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.41% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Humacyte has recently decreased by 2.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.41% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Humacyte has recently decreased by 2.60%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment-0.44 News SentimentHumacyte has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Humacyte this week, compared to 8 articles on an average week.Search Interest18 people have searched for HUMA on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows3 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,466,382.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Humacyte is held by insiders.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Stock News HeadlinesHumacyte (NASDAQ:HUMA) CEO Laura Niklason Sells 591,685 SharesAugust 21 at 7:45 AM | insidertrades.comWall Street Zen Downgrades Humacyte (NASDAQ:HUMA) to SellAugust 19, 2025 | americanbankingnews.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 23 at 2:00 AM | Weiss Ratings (Ad)What is HC Wainwright's Estimate for Humacyte Q3 Earnings?August 16, 2025 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Price Target Cut to $3.50 by Analysts at TD CowenAugust 14, 2025 | americanbankingnews.comHC Wainwright Cuts Humacyte (NASDAQ:HUMA) Price Target to $3.00August 14, 2025 | americanbankingnews.comHumacyte’s Earnings Call: Progress Amid ChallengesAugust 13, 2025 | msn.comHumacyte Inc. (HUMA) Stock Price Today - WSJAugust 12, 2025 | wsj.comSee More Headlines HUMA Stock Analysis - Frequently Asked Questions How have HUMA shares performed this year? Humacyte's stock was trading at $5.05 at the beginning of the year. Since then, HUMA shares have decreased by 68.7% and is now trading at $1.58. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) released its quarterly earnings results on Monday, August, 11th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.09. The firm earned $0.30 million during the quarter, compared to the consensus estimate of $0.94 million. Read the conference call transcript. Who are Humacyte's major shareholders? Top institutional shareholders of Humacyte include CenterBook Partners LP (2.21%), Geode Capital Management LLC (1.90%), Marshall Wace LLP (1.70%) and Bank of America Corp DE (0.32%). Insiders that own company stock include Gordon M Binder, Kathleen Sebelius, Dale A Sander, William John Scheessele, Michael T Constantino, Shamik J Parikh, Heather Ledbetter Prichard, Laura E Niklason and Brady W Dougan. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Humacyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/11/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HUMA CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Price Target for Humacyte$10.64 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+573.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.70 million Net MarginsN/A Pretax Margin-7,171.27% Return on EquityN/A Return on Assets-78.26% Debt Debt-to-Equity Ratio2.97 Current Ratio2.45 Quick Ratio1.93 Sales & Book Value Annual Sales$1.57 million Price / Sales156.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book52.67Miscellaneous Outstanding Shares155,120,000Free Float147,208,000Market Cap$245.09 million OptionableOptionable Beta1.90 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:HUMA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.